Adult and pediatric chronic spontaneous urticaria presents with a high burden of co-occurring type 2 inflammatory diseases alongside a significant non-response rate to standard omalizumab therapy.
Chronic spontaneous urticaria (CSU) remains a debilitating dermatological ailment marked by unpredictable wheals and pruritus. A 10-year multicenter retrospective cohort study across four U.S. allergy practices (two pediatric- and two adult-focused) evaluated the clinical profiles, comorbid type 2 inflammatory conditions, and therapeutic outcomes of 400 patients (189 pediatric, 211 adult) followed for at least six months between 2013 and 2023.
Key Study Findings
This study highlights that both pediatric and adult CSU carry a substantial burden of co-occurring atopic disease and refractory symptoms. The findings underscore a pressing need for standardized clinical documentation and prospective research to delineate CSU endotypes and optimize targeted, individualized therapeutic regimens.
Allergy and Asthma Proceedings
Clinical characteristics, type 2 comorbidities, and treatment responses in pediatric and adult chronic spontaneous urticaria: A multicenter retrospective cohort study
Kathryn Smiley et al.
Comments (0)